Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment

International Journal of Clinical Practice

Volumn 64, Issue 1, 2010, Pages 19-24

  Yazisiz, V ^a   Ongut G ^a   Terziolu E ^a   Karayalcin U ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; THYROID ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; COLD; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOFLUORESCENCE; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; TOXIC GOITER; VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PROPYLTHIOURACIL; THYROID FUNCTION TESTS; YOUNG ADULT;

EID: 72449160696     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01485.x     Document Type: Article

References (22)

1. Savige J, Davies D, Falk RJ et al. Antineutrophil cytoplasmic antibodies and associated: a review of the clinical and laboratory features. Kidney Int 2000 57 : 846 862.
2. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic and crescentic glomerulonephritis. N Engl J Med 1988 318 : 1651 1657.
3. Gunton JE, Stiel J, Clifton-Bligh P et al. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000 142 : 587 590.
4. Sato H, Hattori M, Fujieda M et al. High prevalence of antineutrophil cytoplasmic antibody positive in childhood onset Graves disease treated with propylthiouracil. J Clin Endocrinol Metab 2000 85 : 4270 4273.
5. Hapaala AM, Soppi E, Hyoty H et al. Cross-reactivity between antibodies to thyroid microsomal and myeloperoxidase. Lancet 1991 337 : 803.
6. Dolman KM, Gans RO, Vervaat TJ et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993 342 : 651 652.
7. Kitahara T, Hiromura K, Maezawa A et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol 1997 47 : 336 340.
8. Sorribes MM, Welinder NR, Stangerup SE. Anti-neutrophil cytoplasmic antibody-associated mucocutaneous allergic vasculitis with oral manifestations caused by propylthiouracil. J Laryngol Otol 1999 113 : 477 479.
9. Wang LH, Tsai MJ, Tsai WY et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-positive anaphylactoid purpura-like vasculitis: a case report. J Formos Med Assoc 2000 99 : 642 645.
10. Güldiken S, Arikan E, Ùur B, Tùrul A. Propylthiouracil-induced vasculitis with antineutrophil cytoplasmic autoantibodies in hyperthyroidism: case report. Turkish J Endocrinol Metab 2001 2 : 79 82.
11. Sera N, Ashizawa K, Ando D et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000 10 : 595 599.
12. Noh JY, Asari T, Hamada N et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001 54 : 651 654.
13. Dhillon SS, Singh D, Doe N et al. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999 116 : 1485 1488.
14. Savige J, Gillis D, Benson E et al. International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999 111 : 507 513.
15. Iyode M, Kuroki A, Kato K et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated cresentic glomerulonephritis in a patient with a predisposition to autoimmune abnormalities. Mod Rheumatol 2003 13 : 173 176.
16. Becker BA, Fenves AZ, Breslau NA. Membranous glomerulonephritis associated with Graves disease. Am J Kidney Dis 1999 33 : 369 373.
17. Kudoh Y, Kuroda S, Shimamoto K, Limura O. Propylthiouracil-induced rapidly progressive glomerulonephritis with antineutrophil cytoplasmic autoantibodies. Clin Nephrol 1997 48 : 41 3.
18. Vassilopoulos D, Hoffman GS. Clinical utility of testing for antineutrophil cytoplasmic antibodies. Clin Diagn Lab Immunol 1999 6 : 645 651.
19. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int 1998 53 : 743 753.
20. Jiang X, Khuursigara G, Rubin RL. Transformation of lupus inducing drugs to cytotoxic products by activated neutrophils. Science 1994 266 : 810 813.
21. Lee E, Miki Y, Katsura H, Kariya K. Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 1990 39 : 1467 1471.
22. Yu F, Zhao MH, Zhang YK et al. Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU) induced ANCA positive vasculitis are associated with disease activity. Clin Exp Immunol 2005 139 : 569 574.